Evidence map›Paper›PMID 9826363›Full record

ArticleInfection and immunity1998

Modulation of lipopolysaccharide-induced monocyte activation by heparin-binding protein and fucoidan.

M Heinzelmann, H C Polk, F N Miller

Open access · bronzeAbstract read
In one paragraph

Article in Infection and immunity, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 49 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. CD14 and toll-like receptors 2 and 4 are required for fibrillar A{beta}-stimulated microglial activation.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2009
    Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

M HeinzelmannDepartment of Physiology and Biophysics, Department of Surgery, University of Louisville, School of Medicine, Louisville, Kentucky, USA. mheinzelmann@bluewin.ch
H C Polk
F N Miller
Institute of Molecular Biology and Biophysics · RUUniversity of Louisville · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Activated polymorphonuclear leukocytes release heparin-binding protein (HBP; also known as CAP37 or azurocidin) from azurophilic granules. HBP is a strong chemoattractant for monocytes that also prolongs monocyte survival and potentiates endotoxin (lipopolysaccharide [LPS])-induced production of tumor necrosis factor alpha (TNF-alpha). We investigated the binding of fluorescein isothiocyanate-conjugated HBP to human monocytes in the presence of EDTA and the polysaccharide fucoidan. EDTA, which chelates divalent cations, has been widely used to study the role of divalent cations in receptor-ligand interactions or enzyme activity. Fucoidan has been used to inhibit the binding of various ligands to scavenger receptors or selectins. Scavenger receptors are multiligand receptors that mediate endocytosis of proteases, protease-inhibitor complexes, lipoproteins, and LPS-lipid A. Fucoidan also interferes with leukocyte rolling by binding to L-selectins (expressed on leukocytes) and P-selectins (expressed on platelets and endothelium). We demonstrate that the binding of the neutrophil-derived protein HBP to monocytes is inhibited in the presence of EDTA and fucoidan. In addition, fucoidan and EDTA abrogate the enhancing effect of HBP on LPS-induced TNF-alpha production. These data provide supporting evidence that HBP binds to a receptor expressed on monocytes. This receptor is dependent on divalent cations and is possibly related to the scavenger receptor. Furthermore, we demonstrate that fucoidan, by itself, stimulates TNF-alpha release from isolated monocytes in a CD14-independent fashion. This is an important finding for the interpretation of results from studies that use fucoidan to "block" either scavenger receptors or L- or P-selectins.

Indexed as

Antimicrobial Cationic PeptidesBlood ProteinsCarrier ProteinsDrug InteractionsEdetic AcidHumansLigandsLipopolysaccharide ReceptorsLipopolysaccharidesMonocyte Chemoattractant ProteinsMonocytesNeutrophilsPolysaccharidesProtein BindingReceptors, ImmunologicTumor Necrosis Factor-alphaAntimicrobial Cationic PeptidesAZU1 protein, humanBlood ProteinsCarrier ProteinsEdetic Acidfucoidanheparin-binding protein receptorLigandsLipopolysaccharide ReceptorsLipopolysaccharidesMonocyte Chemoattractant ProteinsPolysaccharidesReceptors, ImmunologicTumor Necrosis Factor-alpha

Identifiers

PMID9826363
PMCPMC108739
OpenAlexW1860887963

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.